Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
General Medicine
Reference31 articles.
1. Biologics and biosimilars: what, why and how?
2. An overview of FDA-approved biologics medicines
3. Treatment of inflammatory bowel disease (IBD)
4. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
5. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue;Journal of Neurology;2024-07-11
2. Histologic manifestations of ocrelizumab‐associated intestinal and hepatic injury in patients with multiple sclerosis;Histopathology;2023-12-19
3. Immune-mediated colitis associated with ocrelizumab: A new safety risk;Multiple Sclerosis Journal;2023-09
4. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review;Multiple Sclerosis and Related Disorders;2023-07
5. Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review;Frontiers in Pharmacology;2023-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3